Author

Makoto Naganuma 1

1 Keio University School of Medicine

ADALIMUMAB ACHIEVES COMPLETE REMISSION AT 52 WEEKS IN JAPANESE PATIENTS WITH INTESTINAL BEHÇET'S DISEASE

Fumihito Hirai, Satoshi Tanida, Nagamu Inoue, Makoto Naganuma, Anne Camez, Bidan Huang, Vipin Arora, Morio Ozawa, Toshifumi Hibi, Roopal B Thakkar

CLINICAL CHARACTERISTICS IN ULCERATIVE COLITIS PATIENTS WITH COLITIS ASSOCIATED DYSPLASIA/CANCER AND SPORADIC TUMOR 

Makoto Mutaguchi, Makoto Naganuma, Yasushi Iwao, Tomohiro Fukuda, Shinya Sugimoto, Kosaku Nanki, Shinta Mizuno, Haruhiko Ogata, Takanori Kanai

INDIGO NATURALIS IS EFFECTIVE FOR INDUCING CLINICAL REMISSION AND MUCOSAL HEALING IN PATIENTS WITH ULCERATIVE COLITIS (INDIGO STUDY)

Makoto Naganuma, Shinya Sugimoto, Keiichi Mitsuyama, Taku Kobayashi, Naoki Yoshimura, Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Kenji Watanabe, Takayuki Abe, Yasuo Suzuki, Toshifumi Hibi, Takanori Kanai

INTRAVENOUS INJECTION OF COLON CANCER EXTRACELLULAR VESICLES SUPPRESSES TUMOR GROWTH WITH DAMPENING REGULATORY T CELL PHENOTYPE

Sanshiro Kobayashi, Takashi Tomiyama, Makoto Naganuma

MR ENTEROCOLONOGRAPHY CAN IDENTIFY PATIENTS WHO NEED ADDITIONAL TREATMENT BY PREDICTING RECURRENCE, HOSPITALIZATION AND SURGERY OF CROHN’S DISEASE PATIENTS IN REMISSION.

Toshimitsu Fujii, Makoto Naganuma, Kento Takenaka, Masakazu Nagahori, Eiko Saito, Kazuo Ohtsuka, Mamoru Watanabe

MR ENTEROCOLONOGRAPHY IS USEFUL TO PREDICT CLINICAL RECURRENCE OF CROHN'S DISEASE AND IDENTIFY PATIENTS WHO NEED MORE AGGRESSIVE TREATMENT.

Toshimitsu Fujii, Makoto Naganuma, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe

Item 1 - 6 / 10
1